Previous 10 | Next 10 |
Results from a Phase 3b clinical trial, ALPINE , evaluating Alkermes plc's (NASDAQ: ALKS ) ARISTADA (aripiprazole lauroxil) and Johnson & Johnson (NYSE: JNJ ) unit Janssen Pharmaceuticals' INVEGA SUSTENNA (paliperidone palmitate) in 200 patients experiencing acute exacerbations of sc...
-- Large, randomized ALPINE trial showed both long-acting injectable medications effectively controlled schizophrenia symptoms throughout six-month study -- -- ARISTADA demonstrated significant and similar efficacy to current market-leader INVEGA SUSTENNA, with differences in safet...
DUBLIN , April 8, 2019 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that Jim Robinson , President and Chief Operating Officer, has resigned from his position and will leave the company, effective April 19, 2019 , for personal reasons. "The past year has be...
-- The Second Annual ALKERMES PATHWAYS RESEARCH AWARDS (SM) Program Will Provide Funding for Up To Eight Research Projects With Individual Grant Amounts of Up To $100,000 per Project -- -- Applications Open for Submission Now Through July 31, 2019 -- DUBLIN ,...
— Company to Host Investor Conference Call at 8:00 a.m. ET on Friday , April 12 — — Poster Presentations to Highlight New Data on ARISTADA® and ALKS 3831 — DUBLIN , April 1, 2019 /PRNewswire/ -- Alkermes plc (Nasdaq:...
The FDA approves Merck KGaA ( OTCPK:MKGAY ) unit EMD Serono's Mavenclad (cladribine) tablets for the treatment of relapsing forms of multiple sclerosis (MS). More news on: Merck KGaA ADR, Celgene Corporation, Roche Holding AG, Healthcare stocks news, Read more ...
In testimony before a Senate Appropriations Subcommittee about the FDA's 2020 budget request, Commissioner Scott Gottlieb, M.D. emphasized the importance of a relatively paltry additional $55M to continue the agency's work combating the opioid crisis. More news on: Endo International plc...
The FDA approves Novartis' (NYSE: NVS ) Mayzent (siponimod) for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome (defined as a first episode of neurologic symptoms that lasts at least 24 hours and is caused by inflammation or demyelinatio...
Privately held Purdue Pharma LP has agreed to pay the state of Oklahoma $270M to settle litigation from the AG's office over its role in the opioid crisis there. More news on: Endo International plc, INSYS Therapeutics, Inc., Titan Pharmaceuticals, Inc., Healthcare stocks news, Stocks on...
Life is either a daring adventure or nothing at all. ” - Helen Keller Today, we take a look at three small biotech stocks that are seeing some recent insider buying. I have always viewed insider buying as a positive when evaluating stocks in different sectors. Given the complexity ...
News, Short Squeeze, Breakout and More Instantly...
Alkermes plc (ALKS) is expected to report $0.64 for Q2 2024 Acerinox ADR (ANIOY) is expected to report for Q2 2024 Allegion plc (ALLE) is expected to report $1.77 for Q2 2024 Deutsche Bank AG (DB) is expected to report $0.43 for Q2 2024 Pathward Financial Inc. (CASH) is expected t...
Alkermes plc Reports Second Quarter 2024 Financial Results PR Newswire — Second Quarter Revenues of $399.1 Million — — Net Sales of Proprietary Products Increased Approximately 16% Year-Over-Year — — GAAP Net Income from C...
2024-07-22 10:45:03 ET Enbridge Inc (ENB) ENB is trading UP for the last 5 days, and it at trading at $36.59 with volume of 731,965 and a one day change of $0.05 (0.14%). Enbridge Inc has a 52-week low of 31.03 and a 52-week high of $38.36. The business's 50-day moving average price...